Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

2013 JIB Congress to Emphasize New Perspectives in Medical Biology

By BiotechDaily International staff writers
Posted on 15 Jul 2013
A new governance has been set up to organize the next Journées Internationales de Biologie (JIB; Paris, France), its 58th annual meeting of medical biologists, to be held November 13–15, 2013 at the CNIT Paris, La Défense. In order to place the congress as a key "laboratory agenda" professional event, JIB renews itself not only as a recurring gathering for the profession, but also as an opportunity to gain fresh, positive perspectives on one's daily practice in the laboratory.

In order to optimize attendee presence at the meeting, efficiency is emphasized in enabling participants in each area to gather, individually or collectively, in a productive manner. Medical biologists can find solutions in various missions (HR, quality, logistics, finance, etc.) and fields (hematology, virology, biochemistry, etc.) by their participation in the congress, the exhibition, and the JIB Awards. Discussions and exchanges between specialists take place on the "Paroles d’Experts.” The "Institutions Corner" brings together various authorities for the profession (regional associations, societies, orders, ministries, syndicates, or humanitarians). JIB is also committed to the new generation and has dedicated the "Recruitment Sphere" section with practical workshops to help facilitate access and integration of new biologists to the professional world.

The exhibition platform for launching innovations will present nearly 200 technological advances and solutions, of which 75% have a European and worldwide scope, and 78% are presented for the first time. Innovation is particularly visible at the "Innovation Gallery," and is further emphasized at the JIB Awards ceremony, provided for the second time after its success in 2012, now with six new categories: Procedures Improvement, Innovation Gallery, Quality and Accreditation, Emergency Biology and POC, Post Analytics Innovation, and the Jury’s Award.

The congress sessions mainly relate to the multidisciplinary aspect of medical biology, innovative laboratory equipment and technologies, and the role of biology in healthcare policies and organization. The inaugural session “Medical biology and screening policies” highlights biology in preventive and individualized medicine as the desired alternative to curative medicine. The session on “Nanotechnologies, first outcomes and perspectives in medical biology” presents an overview of the miniaturized technologies that are transforming diagnosis and follow-up methods. In parallel to the scientific sessions, the "Colloquium" offers working sessions to assist with various topics such as laboratory services, the medical biology laboratory in local health policies, and the evolution of the biomedical practice organization.

Related Links:

JIB - Journées Internationales de Biologie





comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.